Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P51692
UPID:
STA5B_HUMAN
Alternative names:
-
Alternative UPACC:
P51692; Q8WWS8
Background:
Signal transducer and activator of transcription 5B (STAT5B) plays a pivotal role in cellular responses to cytokines and growth factors. It is essential for mediating the effects of KITLG/SCF and supports hematopoietic/erythroid differentiation by binding to the GAS element and activating transcription.
Therapeutic significance:
STAT5B mutations are linked to Growth hormone insensitivity syndrome with immune dysregulation, both autosomal recessive and dominant forms. These conditions are characterized by growth hormone resistance, short stature, and immune dysregulation, highlighting STAT5B's potential as a therapeutic target.